pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$UTHRUNITED THERAPEUTICS Corp

$UTHR587.88-0.56%
Silver Spring, MD, USupdated 7h ago

United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
4
phase 3
2
catalysts ytd
6
approvals ytd
1
recalls ytd
0

Pipeline(6)

pipeline depth6 products
Phase 3: 2Marketed: 4
2Phase 34Marketed
Marketed
Remodulin
Pulmonary Arterial Hypertension
Marketed
Tyvaso DPI
Pulmonary Arterial Hypertension
Marketed
dinutuximab
Neuroblastoma
Marketed
treprostinil diolamine ER
Pulmonary Arterial Hypertension
Phase 3
ralinepag XR
Pulmonary Arterial Hypertension
Prostacyclin receptor
Phase 3
treprostinil
Idiopathic Pulmonary Fibrosis
Prostacyclin receptor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (2)
Nov 4, 2026
earnings
$UTHR587.88-0.56%
13d ago
UNITED THERAPEUTICS Corp earnings
UNITED THERAPEUTICS Corp
→
Oct 28, 2026
earnings
$UTHR587.88-0.56%
20d ago
UNITED THERAPEUTICS Corp earnings
UNITED THERAPEUTICS Corp
→
view all catalysts →

Active trials

  • phase3An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)not yet recruitingn=400
  • phase3Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Diseaseenrolling by invitationn=1,850
  • phase2Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDrecruitingn=50
  • phase3Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjectsterminatedn=10
  • phase3Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)recruitingn=698
  • N/AStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)recruitingn=346
  • —DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)recruitingn=900
  • phase3A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patientscompletedn=687
🐶 Hiring Signal
No open roles indexed yet — view UNITED THERAPEUTICS Corp jobs →

News

  • Spyre’s arthritis misses; Ideaya ends eye cancer trial
    Plus news about United Therapeutics. Spyre Therapeutics reports additional trial failures: The biotech said its long-acting anti-TL1A drug, codenamed SPY072, did not meet the primary endpoints in t…
    endpoints · 12d ago
  • Sanofi's new German site; radioisotope deals from Northstar and Telix
    Plus more from Baxter and United Therapeutics. Sanofi starts construction of an insulin factory: Sanofi has broken ground on a new 36,000-square-meter manufacturing facility at its site in Frankfur…
    endpoints · 25d ago
  • Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump
    Plus news about United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmak…
    endpoints · 1mo ago
  • STAT+: FDA adcomm members’ ties to industry under scrutiny
    New research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…
    stat · 1mo ago
  • Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
    CEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
    biospace · 1mo ago
  • Varda raises $251M to leverage gravity in space for drug production
    Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.
    biospace · 1mo ago
  • United Therapeutics' legal victory; BMS' Camzyos approved for kids
    Plus, news about United Therapeutics, MindRank, Novo, Atara Biotherapeutics, Pierre Fabre, Monte Rosa Therapeutics, Bristol Myers Squibb’s Camzyos and Skopos Bio. Nektar Therapeutics' shares drop 2…
    endpoints · 1mo ago
  • Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
    Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, 'significantly exceeded expectations' in reducing pulmonary vascular resistance, according to analysts, and is progressing…
    biospace · 2mo ago
  • FDA extends review of Capricor cell therapy; Pain drug startup to go public
    The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
    biopharma_dive · 2mo ago
  • Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
    Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.
    fiercebiotech · 3mo ago
view all news mentions →
identifiers
ticker
$UTHR
SEC CIK
0001082554
country
US
source
sec_tickers
top tags
Cardiology3Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 58m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?